BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36001789)

  • 1. Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas.
    Johnson PC; Abramson JS
    Oncology (Williston Park); 2022 Aug; 36(8):499-505. PubMed ID: 36001789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
    Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
    Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
    J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.
    Kuhlman JJ; Moustafa MA; Jiang L; Iqbal M; Seegobin K; Wolcott Z; Ayala E; Ansell S; Rosenthal A; Paludo J; Micallef I; Johnston P; Inwards D; Habermann T; Kharfan-Dabaja M; Witzig TE; Nowakowski GS; Tun HW
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e815-e825. PubMed ID: 35534379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.
    Hüttl KS; Staiger AM; Richter J; Ott MM; Kalmbach S; Klapper W; Biesdorf AS; Trümper L; Rosenwald A; Ziepert M; Horn H; Ott G
    Virchows Arch; 2021 Sep; 479(3):575-583. PubMed ID: 33655392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.
    Bischin AM; Dorer R; Aboulafia DM
    Clin Med Insights Blood Disord; 2017; 10():1179545X17692544. PubMed ID: 28579851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.
    Sermer D; Bobillo S; Dogan A; Zhang Y; Seshan V; Lavery JA; Batlevi C; Caron P; Hamilton A; Hamlin P; Horwitz S; Joffe E; Kumar A; Matasar M; Noy A; Owens C; Moskowitz A; Palomba ML; Straus D; von Keudell G; Rodriguez-Rivera I; Falchi L; Zelenetz A; Yahalom J; Younes A
    Blood Adv; 2020 Jul; 4(14):3382-3390. PubMed ID: 32722781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
    Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
    Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inferior survival in high-grade B-cell lymphoma with
    McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
    Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [MYC-associated B-cell lymphomas: pathophysiology and treatment].
    Nitta H
    Rinsho Ketsueki; 2019; 60(3):155-164. PubMed ID: 31068510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
    Zayac AS; Landsburg DJ; Hughes ME; Bock AM; Nowakowski GS; Ayers EC; Girton M; Hu M; Beckman AK; Li S; Medeiros LJ; Chang JE; Stepanovic A; Kurt H; Sandoval-Sus J; Ansari-Lari MA; Kothari SK; Kress A; Xu ML; Torka P; Sundaram S; Smith SD; Naresh KN; Karimi YH; Epperla N; Bond DA; Farooq U; Saad M; Evens AM; Pandya K; Naik SG; Kamdar M; Haverkos B; Karmali R; Oh TS; Vose JM; Nutsch H; Rubinstein PG; Chaudhry A; Olszewski AJ
    Blood Adv; 2023 Nov; 7(21):6381-6394. PubMed ID: 37171397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining and treating high-grade B-cell lymphoma, NOS.
    Olszewski AJ; Kurt H; Evens AM
    Blood; 2022 Sep; 140(9):943-954. PubMed ID: 34525177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
    Xia Y; Zhang X
    Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].
    Misyurina AE; Kravchenko SK; Kovrigina AM; Magomedova AU; Plastinina LV; Obukhova TN; Misyurin AV; Misyurin VA; Grebenuk LA; Babaeva FE; Baryakh EA; Vorobiev AI
    Ter Arkh; 2019 Jul; 91(7):52-62. PubMed ID: 32598736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational landscape of high-grade B-cell lymphoma with
    Künstner A; Witte HM; Riedl J; Bernard V; Stölting S; Merz H; Olschewski V; Peter W; Ketzer J; Busch Y; Trojok P; Bubnoff NV; Busch H; Feller AC; Gebauer N
    Haematologica; 2022 Aug; 107(8):1850-1863. PubMed ID: 34788985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell Lymphoma, Not Otherwise Specified.
    Qiu L; Lin P; Khanlari M; Xu J; Cohen EN; Garces S; Miranda RN; Wang W; Fang H; Bueso-Ramos CE; Medeiros LJ; Li S
    Mod Pathol; 2023 Dec; 36(12):100349. PubMed ID: 37820764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.